AI Article Synopsis
- - The study aimed to compare the effectiveness and safety of methadone versus buprenorphine for treating opioid-dependent pregnant women, conducted at a clinic in Vienna with 18 participants.
- - Participants were randomly assigned to receive either methadone or buprenorphine, and results indicated better retention rates in the buprenorphine group while the methadone group experienced less concurrent opioid use.
- - Findings suggested that neonates exposed to methadone had an earlier onset of neonatal abstinence syndrome (NAS) compared to those exposed to buprenorphine, highlighting the need for further research in this area.
Article Abstract
Aims: To evaluate the efficacy and safety of methadone versus buprenorphine treatment in pregnant opioid-dependent women.
Design: Randomized, double-dummy, double-blind, flexible-dosing comparison study.
Setting: Addiction Clinic at the Medical University of Vienna, Austria.
Participants: Eighteen women were assigned randomly to receive either methadone (n = 9) or buprenorphine (n = 9) during weeks 24-29 of pregnancy. After dropouts, data were available from 14 cases (six in the methadone and eight in the buprenorphine group).
Intervention: Sublingual buprenorphine tablets (8-24 mg/day) or oral methadone solution (40-100 mg/day), with matched placebos.
Measurements: Mothers: retention in treatment, urine toxicology and nicotine use. Neonates: Routine birth data, neonatal abstinence syndrome (NAS) in severity and duration.
Findings: There was somewhat greater retention in the buprenorphine group but significantly lowered use of additional opioids in the methadone group (P = 0.047).Neonates: There was earlier onset of NAS in neonates born to the methadone (mean 60 hours) than to the buprenorphine groups (mean 72 hours after last medication); 43% did not require NAS-treatment with short treatment duration in both groups (mean 5 days).
Conclusion: This preliminary study had limited power to detect differences but the trends observed suggest this kind of research is practicable and that further studies are warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1360-0443.2006.01321.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aims: We measured the association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy (OAT) for opioid use disorder.
Design: Retrospective cohort study using the British Columbia Provincial Overdose Cohort, a linked administrative database.
Setting: We used data from British Columbia, Canada, from January 2015 through February 2020.
Perinatal exposure to methadone or buprenorphine impairs hippocampal-dependent cognition and brain development in juvenile rats.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
School of Psychology, University of New South Wales, Sydney, Australia. Electronic address:
The opioid crisis continues to escalate, disproportionately affecting women of reproductive age. Traditionally the first line of treatment for pregnant women with opioid use disorder is the mu-opioid receptor agonist methadone. However, in recent years, the use of buprenorphine as a replacement therapy has increased as it has fewer side-effects and longer duration of action.
View Article and Find Full Text PDFPerioperative analgesic effects of a modified supratemporal retrobulbar block in dogs undergoing corneal and endocular surgery.
J Small Anim Pract
January 2025
Department of Veterinary Science, University of Turin, Grugliasco, Italy.
Objectives: To evaluate the perioperative efficacy of a modified supratemporal retrobulbar block in dogs undergoing ocular surgery.
Materials And Methods: In this prospective randomized clinical trial, dogs were premedicated with dexmedetomidine (1 mcg/kg im) and methadone (0.1 mg/kg im), induced with propofol to effect and maintained with isoflurane (FE'Iso 1.
A cross-sectional study of differences in medication for opioid use disorder receipt among pregnant people enrolled in Medicaid in Oregon, United States.
Addiction
January 2025
Center for Health Systems Effectiveness, Department of Emergency Medicine, Oregon Health and Science University, Portland, OR, USA.
Background And Aims: Medication is the gold standard to support a healthy pregnancy for pregnant people with opioid use disorder (OUD). This study measured inequities and differences in OUD medication treatment among pregnant people in Oregon, USA.
Design, Setting, Participants And Measurements: Our study population consisted of Medicaid enrollees across the US state of Oregon who had at least one live hospital birth between 2012 and 2020 and one diagnosis of OUD prenatally (n = 4363).
Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.
Drug Alcohol Depend
February 2025
Neuropsychoimaging of Addictions and Related Conditions (NARC), Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Question: The opioid epidemic causes massive morbidity, and males have substantially greater overdose mortality rates than females. It is unclear whether there are sex-related disparities at different stages in the trajectory of opioid use disorders (OUD), from large samples in the community.
Goal: To determine sex disparities in non-medical opioid use (NMOU) at the end of treatment with medications for opioid use disorder (MOUD), using national data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!